US 11311544
Treatment of congenital adrenal hyperplasia
granted A61KA61K31/427A61K31/4985
Quick answer
US patent 11311544 (Treatment of congenital adrenal hyperplasia) held by Neurocrine Biosciences, Inc. expires Mon Apr 21 2042 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Neurocrine Biosciences, Inc.
- Grant date
- Tue Apr 26 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Apr 21 2042 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 28
- CPC classes
- A61K, A61K31/427, A61K31/4985, A61K31/519, A61P